Business plan

Neursantys Wins $10,000 Business Plan Competition at What’s Next Longevity Venture Summit 2022

CHICAGO, ILLINOIS, USA, June 30, 2022 / — Neursantys (, based in Chicago, Illinois and Calgary, Alberta, has been selected as the winner of the What’s Next Longevity Venture Summit 2022 $10,000 Business Plan Competition. Now in its 20th year, the What’s Next Longevity Venture Summit brings together leading authorities on future trends in America’s $8.3 trillion longevity economy, including investors and entrepreneurs at the intersection of the ageing, technology and investment. Companies from around the world submitted business plans to the competition, developing innovative products and services addressing chronic disease management, balance and mobility disorders, hearing care, healthcare worker shortages and improving the quality of life of the elderly. The winner was selected by a panel of six judges representing the best investors in the longevity market.

“By developing the first easy-to-use, portable device that integrates balance diagnosis and therapeutic treatment, Neursantys is providing an innovative solution to the problem of age-related decline in balance that affects 60 million people in the United States. United States, increasing the risk of fall-related injuries and making it increasingly difficult to continue living an active and independent life,” said Mary Furlong, Founder and CEO of Mary Furlong Associates and Executive Producer of What’s Next Longevity Summit events. . “We are thrilled to present this year’s award to Neursantys for the transformational improvements in quality of life they can enable older adults around the world.

“Until now, there have been no widely available therapeutic treatments for these impairments, so the only solution available to most older adults is a mechanical balance aid such as a walker,” John said. Ralston, CEO of Neursantys. “But relying on these devices can actually degrade balance even further and hasten the loss of an active, independent lifestyle. The Neursantys team is honored to be recognized by the Longevity Venture Summit for their commitment to revolutionizing diagnosis and treatment of age-related balance disorders.

Neursantys CEO John Ralston was interviewed on the June 21 Longevity Deal Talk podcast by Mary Furlong and Fred Fishkin, co-host of Mary’s podcast, and was joined by Mel Barsky, moderator of the business plan competition. $10,000 business and Director of Business Development at the Center for Aging + Brain Health Innovation (CABHI) based in Toronto, Canada. The 2022 Longevity Venture Summit conference proceedings can be viewed online through the end of August 2022 at

# # #

About Neursantys (
With offices in Chicago, Illinois and Calgary, Alberta, Neursantys integrates the company’s innovations in wearable neurophysiological disorder detection, noninvasive neurostimulation and machine learning into a powerful new class of wearable devices that can deliver both the diagnostic detection and therapeutic correction of neurophysiological impairments caused by aging, injury and disease. The company’s first product, NEURVESTA, addresses age-related balance degeneration, which causes the average person to lose 40% of their balance function by the age of 70. By enabling tens of millions of people to continue living active and independent lives for much longer, the NEURVESTA device and associated services are positioned to become a cornerstone of the rapidly growing longevity economy.

About What’s Next Longevity Venture Summit (
Now in its 20th year, the What’s Next Longevity Venture Summit is the first of its kind and one of the most important gatherings of economically-focused venture capitalists, angel investors, entrepreneurs and business leaders. of longevity. Attracting more than 300 leaders in the fields of aging and health, it’s where forward-thinking entrepreneurs and VCs meet to create innovative products and services for the global longevity market.

Media inquiries:

Jean Ralston
Neursantys, Inc.
[email protected]
Visit us on social media: